Gold prices steady ahead of Fed decision, Trump’s tariff deadline
Investing.com -- Pfizer (NYSE:PFE), the pharmaceutical giant, may consider relocating its overseas manufacturing to the U.S., according to a statement by its CEO Albert Bourla on Monday. This potential move comes as the Trump administration continues to threaten the imposition of numerous tariffs on imported goods.
Albert Bourla, the CEO of Pfizer, stated that the company is prepared to move its overseas manufacturing to the U.S. if necessary. This statement comes in light of the ongoing tariff threats from the Trump administration. The pharmaceutical giant is one of many companies potentially affected by the proposed tariffs on imported goods.
No specific timeline or plan for this potential move has been announced by Pfizer. The company’s decision will likely depend on the final actions of the Trump administration regarding the threatened tariffs. Pfizer is currently monitoring the situation and will make decisions based on the best interests of the company and its stakeholders.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.